Drugs Made In America Acquisition Corp. Rights (DMAAR) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Drugs Made In America Acquisition Corp. Rights, updated every trading day.
Finance · Blank Checks
Price
$0.10
−12.71% today
Market cap
—
Overall quality
53/100
Kronos AI 30-day
—
Drugs Made In America Acquisition Corp. Rights (DMAAR) is a Finance company in Blank Checks. It trades at $0.10, down 12.71% today, at 0.3 times earnings. Its overall quality score is 53 out of 100, ranked against the whole US market.
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
No analyst covers this listing yet.
Kronos AI 30-day forecast
No forecast for this listing.
Quality scores
| Profitability | 50 |
| Solvency | 65 |
| Growth | 44 |
| Overall | 53 |
| P/E | 0.3 |
Shariah screen
| Business activity | Does not pass |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Blank Checks
For information only, not investment advice. Prices updated: 2026-10-29.